Navigation Links
Researchers add new tool to tumor-treatment arsenal

A new study demonstrates the potential effectiveness of treating tumors by combining agents that damage DNA with a drug that sensitizes cancer cells to these agents.

The research, led by George Thomas, PhD, professor at the University of Cincinnati's (UC) Genome Research Institute, and Heidi Lane of Novartis Institutes for Biomedical Research, appears in the March 25, 2005, issue of the journal Cell.

Dr. Thomas and a co-author Stefano Fumagalli, PhD, began this research while working at the Friedrich Miescher Institute for Biomedical Research in Basel, Switzerland, and completed these studies at UC's Genome Research Institute, where further studies continue.

"The use of DNA-damaging agents has revolutionized chemotherapy against a wide variety of cancers," says Dr. Thomas. "However, a narrow therapeutic window, combined with possible severe side effects, has greatly limited their broader use."

These factors, says Dr. Thomas, have probably contributed to recent reports of the under-dosing of patients and the failure to blunt the disease.

When cancer cells are treated with a DNA-damaging agent, a cancer-suppressing gene known as the "guardian of the cell" (a protein called p53) responds by either killing the cell, if the damage is too severe, or allowing the cancer cell to repair the damaged DNA. If the DNA is repaired, cells can continue to multiply.

The dilemma is that high doses of DNA-damaging agents can be toxic, and doses that are too low allow for DNA repair and further cell growth. Thus, says Dr. Thomas, there is need for drugs that can sensitize cells to lower doses of DNA-damaging agents to guarantee cell death, but without the toxic side effects.

The researchers studied the results of combining a DNA-damaging agent called cisplatin with RAD001, a derivative of the immunosuppressive drug rapamycin. Used in organ transplant patients, rapamycin and its derivatives have shown promising anti-tumor activity i n phase I and II clinical trials.

RAD001 lowers the amount of DNA-damaging agent needed by blocking p53's DNA-repair function, automatically killing the cancer cells when agents like cisplatin are introduced.

"These findings provide the rationale for combining DNA-damaging agents with sensitizing agents like RAD001," says Dr. Thomas. "Since about 50 percent of all solid tumors contain p53, such a drug combination could dramatically improve the treatment of solid tumors."


'"/>

Source:University of Cincinnati


Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
10. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
11. Researchers develop rapid diagnostic tool for pathogen identification
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2018)... ... August 21, 2018 , ... Mandy is an eight-year-old mini Australian shepherd and a ... places. She went through three surgeries to try to repair the leg and each ... use the leg so her owner, along with her veterinarian, decided to amputate. With ...
(Date:8/23/2018)... , ... August 22, 2018 , ... ... of LimitLIS® 4.0, the latest version of its rapidly growing cloud-based laboratory information ... Toxicology Edition, as well as the company’s triple digit growth throughout 2018, the ...
(Date:8/21/2018)... ... August 20, 2018 , ... When designing a ... consider. Designers must ensure what is designed can be manufactured reliably and cost ... practices in flow path design with specific focus on layered manifold technology. , ...
Breaking Biology News(10 mins):
(Date:9/12/2018)... , ... September 12, 2018 , ... ... a quality management professional and former Senior Director of Regulatory Affairs and Quality ... , As Senior Director of Regulatory Affairs and Quality Systems at WellDoc, Inc., ...
(Date:9/7/2018)... , ... September 06, 2018 , ... ... fatal neuromuscular disease, has been validated to be as effective as manual pathology. ... Dystrophin Staining in Frozen Muscle Biopsies,” was published in the Archives of Pathology ...
(Date:8/31/2018)... ... August 30, 2018 , ... Small, wireless and networked describes more than ... getting connected, too. Draper’s latest system is tiny in size, but is poised to ... factor in the new implant design is the growing awareness that disease often involves ...
(Date:8/29/2018)... ... August 28, 2018 , ... CEO and founder ... safety study performed on an allogeneic (donor derived) stem cell product for osteoarthritis ... conference in September. He is also the organizer of Breakout Session 4: ...
Breaking Biology Technology: